Verona Pharma PLC ADR (VRNA)

NASDAQ
Currency in USD
72.690
-1.400(-1.89%)
Closed·
After Hours
72.510-0.180(-0.248%)
·
VRNA Scorecard
Full Analysis
Analysts anticipate sales growth in the current year
VRNA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
72.39075.430
52 wk Range
11.39075.600
Key Statistics
Edit
Prev. Close
74.09
Open
73.77
Day's Range
72.39-75.43
52 wk Range
11.39-75.6
Volume
1.21M
Average Volume (3m)
1.44M
1-Year Change
492.72%
Book Value / Share
2.67
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VRNA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
94.100
Upside
+29.45%
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins
Show more

Verona Pharma PLC ADR Company Profile

Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

Verona Pharma PLC ADR Earnings Call Summary for Q4/2024

  • Q4 2024 EPS of -$0.05 beat -$0.07 forecast; revenue of $35.65M exceeded $6.14M estimate
  • Stock surged 5.98% post-earnings; 254.66% return over past year
  • O2VARE therapy adoption strong with 4,600+ healthcare providers prescribing
  • $400M cash reserves; aiming for cash flow breakeven at $250-300M annual revenue
  • Preparing for European and global regulatory expansion; sustained net losses remain a challenge
Last Updated: 28/02/2025, 02:12 am
Read Full Transcript

Compare VRNA to Peers and Sector

Metrics to compare
VRNA
Peers
Sector
Relationship
P/E Ratio
−40.4x−0.8x−0.5x
PEG Ratio
0.29−0.010.00
Price/Book
29.2x−0.1x2.6x
Price / LTM Sales
55.9x2.2x3.0x
Upside (Analyst Target)
25.3%126.5%48.7%
Fair Value Upside
Unlock31.0%9.2%Unlock

Analyst Ratings

10 Buy
0 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 94.100
(+29.45% Upside)

Earnings

Latest Release
Apr 29, 2025
EPS / Forecast
-0.02 / -0.07
Revenue / Forecast
76.30M / 52.70M
EPS Revisions
Last 90 days

People Also Watch

93.00
BMA
+0.06%
66.16
INSM
+0.21%
95.01
CALM
-1.82%
458.74
GEV
+1.26%
67.33
WGS
-0.66%

FAQ

What Is the Verona Pharma ADR (VRNA) Stock Price Today?

The Verona Pharma ADR stock price today is 72.69

What Stock Exchange Does Verona Pharma ADR Trade On?

Verona Pharma ADR is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Verona Pharma ADR?

The stock symbol for Verona Pharma ADR is "VRNA."

What Is the Verona Pharma ADR Market Cap?

As of today, Verona Pharma ADR market cap is 6.75B.

What Is Verona Pharma ADR's Earnings Per Share (TTM)?

The Verona Pharma ADR EPS (TTM) is -1.98.

When Is the Next Verona Pharma ADR Earnings Date?

Verona Pharma ADR will release its next earnings report on 30 July 2025.

From a Technical Analysis Perspective, Is VRNA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Verona Pharma ADR Stock Split?

Verona Pharma ADR has split 0 times.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.